Elevated levels of TNFRSF1A are also linked with a decreased risk of MS (OR: 0.21; 95% CI, 0.12–0.37), while higher levels of CR1 are positively associated with an increased risk of MS (OR: 1.17; 95% CI, 1.08–1.27). Here, CR1 is linked to myeloid sarcoma.